M Pharmaceutical Provides Update on ToConceive Product

Pharmaceutical Investing

M Pharmaceutical gave an update to shareholders on the release of its FDA-cleared products ToConceive in the North American market.

M Pharmaceutical (CSE:MQ; OTCQB:MPHMF) gave an update to shareholders on the release of its FDA-cleared products ToConceive in the North American market.
As quoted in the press release:

“As someone who endured a long and costly fertility journey (emotional, physical and financial), I’m optimistic about any non-invasive option that can help address fertility related issues and do so much earlier in the journey,” said Kim Whittemore, a recognized women’s sexual health advocate, and M Pharmaceutical Board Member. “The science behind ToConceive is sound and will help many couples avoid more expensive and invasive treatments.”
“Anstice is proud to partner with M Pharmaceuticals as it introduces ToConceive to the market,” said Sheenah Rogers, Founder, and CEO of Anstice Communications. “We will be working closely with M Pharma to implement an effective brand strategy and build a strong awareness of this innovative new product among consumers.”

Click here to read the full press release.

Source: www.accesswire.com

consumers fda health north american sexual health women Pharmaceutical Investing